アルコール使用障害の世界市場：地域・国別の分析・予測 (2025～2035年)

世界のアルコール使用障害の市場は現在ライフサイクルの成長期にあります。

この段階は、革新的な治療法への需要の高まりや、アルコール使用障害が重要な公衆衛生課題として認識されるようになったことを特徴としています。個人の遺伝的プロファイルに基づいて治療法を最適化する個別化医療の進展や、より効果的かつ標的を絞った新しい薬物療法の開発が市場成長の追い風となっています。さらに、薬物療法と行動療法を統合した包括的な治療モデルの普及も市場の拡大に寄与しています。加えて、遠隔医療やオンライン支援プラットフォームなどのデジタルヘルス技術の導入が進み、特に医療サービスが不足している地域においてアルコール使用障害治療へのアクセスが向上しています。また、世界的に依存症治療の医療基盤を強化しようという動きが広がっており、治療の提供範囲と可用性の拡大に貢献しています。こうした機会にもかかわらず、治療コストの高さや依存症に対する社会的偏見といった課題も依然として存在しており、特に発展途上国では治療法の普及を妨げる要因となっています。それでも、公衆衛生キャンペーンなどを通じて認知とアクセス改善が進む中で、市場は今後さらに成長し、より成熟した段階へと移行していくと期待されています。

影響

• アルコール使用障害に対する治療ニーズの高まりは予測期間中の世界市場の成長を後押しする見通し
• 標的治療の進展、認知度と診断率の向上、臨床パイプラインの拡充、医療インフラと専門治療へのアクセス改善が市場を力強く牽引する要因となる見通し

最新の動向

• 研究活動：2025年5月、Adial Pharmaceuticals, Inc.は、米国特許商標庁が特許番号12,274,692号を付与したことを発表。これは、AD04を用いて、遺伝的に定義された患者群に対し、アルコール関連およびオピオイド関連障害を治療する革新的な方法をカバーする特許

当レポートでは、世界のアルコール使用障害の市場を調査し、主要動向、市場影響因子の分析、法規制環境、臨床試験の動向、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

エグゼクティブサマリー

第1章 世界のアルコール使用障害市場：業界展望

• 市場概要とエコシステム
• 市場動向
• アルコール使用障害の疫学的分析
  • 地域別
• 臨床試験
  • フェーズ別
  • スポンサータイプ別
• 規制状況/コンプライアンス
  • 米国の法的要件と枠組み
  • EUにおける法的要件と枠組み
  • アジア太平洋における法的要件と枠組み
• 市場力学
  • 影響分析
  • 市場促進要因
  • 市場抑制要因
  • 市場機会

第2章 世界のアルコール使用障害市場：地域別

• 北米
• 欧州
• アジア太平洋
  • 市場力学
  • 市場規模・予測

第3章 世界のアルコール使用障害市場：競合ベンチマーキング・企業プロファイル

• 競合情勢
  • 各社の主要戦略と展開
  • 主な展開の分析
• 企業プロファイル
  • Clearmind Medicine Inc.
  • Purdue Pharma L.P.
  • Psyence Biomedical
  • Eli Lilly and Company
  • Tempero Bio, Inc.
  • Nxera Pharma Co., Ltd.
  • Novo Nordisk A/S
  • Adial Pharmaceuticals
  • Alkermes
  • Lundbeck

第4章 調査手法

List of Figures

• Figure: Global Alcohol Use Disorder Market, Market Overview
• Figure: Global Alcohol Use Disorder Market Coverage
• Figure: Global Alcohol Use Disorder Market Key Trends, Impact Analysis, 2023-2035
• Figure: Global Alcohol Use Disorder Market, Competitive Landscape, January 2022-April 2025

List of Tables

• Table: Global Alcohol Use Disorder Market, Regulatory Scenario
• Table: Global Alcohol Use Disorder Market Dynamics, Impact Analysis

Market Lifecycle Stage

The global alcohol use disorder market is currently in the growth stage of its lifecycle. This phase is characterized by a rising demand for innovative treatments and increased recognition of alcohol use disorder as a significant public health issue. The market is benefiting from advancements in personalized medicine, where treatments are tailored to individuals based on genetic profiles, as well as the development of new pharmacotherapies that offer more effective and targeted solutions. Additionally, the market is being driven by the growing integration of behavioral therapies with pharmacological treatments, creating more comprehensive and effective care models. Another key factor in the market's growth is the increasing adoption of digital health technologies, including telemedicine and online support platforms, which make alcohol use disorder treatments more accessible, especially in underserved regions. This is coupled with a global push for better addiction treatment infrastructure, expanding both the reach and availability of care. Despite these opportunities, challenges such as high treatment costs and social stigmas related to addiction still persist, especially in developing markets, potentially limiting the broader adoption of treatment solutions. However, as public health initiatives continue to promote awareness and access, the market is expected to grow further and move toward a more mature stage in the coming years.

Impact

• Increasing demand for alcohol use disorder therapies is anticipated to support the growth of the global alcohol use disorder market during the forecast period 2025-2035.
• The global alcohol use disorder market is expected to grow at a significant rate due to developments in targeted therapies, rising awareness and diagnosis, and a growing clinical pipeline, alongside advancements in healthcare infrastructure and access to specialized treatments.

Recent Developments

• Research Activities: In May 2025, Adial Pharmaceuticals, Inc. announced that the U.S. Patent and Trademark Office had issued U.S. Patent No. 12,274,692, covering an innovative method for treating alcohol-related and opioid-related disorders using AD04 in genetically defined patient populations.

Demand - Drivers and Limitations

Drivers:

• Increasing Prevalence of Alcohol Use Disorder
• Improved Diagnostic Criteria and Screening Tools

Limitations:

• Limited Treatment Options for Specific Populations

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Innovations in the global alcohol use disorder market are centered on advancing treatment options to enhance patient care. Key players in the market, such as Adial Pharmaceutical, Inc., have been involved in the development of therapies for alcohol use disorder.

Competitive Strategy: Enterprises led by market leaders continually update their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product pipeline and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolios, and market penetration.

Some of the prominent names established in this market are:

• Clearmind Medicine Inc.
• Purdue Pharma L.P.
• Psyence Biomedical
• Eli Lilly and Company
• Tempero Bio, Inc.
• Nxera Pharma Co., Ltd.
• Novo Nordisk A/S
• Adial Pharmaceuticals
• Alkermes
• Lundbeck

Table of Contents

Executive Summary

Scope of Study

1. Global Alcohol Use Disorder Market: Industry Outlook

• 1.1 Market Overview and Ecosystem
• 1.2 Market Trends
• 1.3 Epidemiological Analysis of Alcohol Use Disorder
  • 1.3.1 By Region
• 1.4 Clinical Trials
  • 1.4.1 By Phase
  • 1.4.2 By Sponsor Type
• 1.5 Regulatory Landscape / Compliance
  • 1.5.1 Legal Requirement and Framework in the U.S.
  • 1.5.2 Legal Requirement and Framework in the E.U.
  • 1.5.3 Legal Requirement and Framework in Asia-Pacific
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Restraints
  • 1.6.4 Market Opportunities

2. Global Alcohol Use Disorder Market, By Region, $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Market Dynamics
  • 2.1.2 Market Size and Forecast
    • 2.1.2.1 North America Alcohol Use Disorder Market (by Country)
      • 2.1.2.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Market Dynamics
  • 2.2.2 Market Size and Forecast
    • 2.2.2.1 Europe Alcohol Use Disorder Market (by Country)
      • 2.2.2.1.1 U.K.
      • 2.2.2.1.2 Germany
      • 2.2.2.1.3 France
      • 2.2.2.1.4 Italy
      • 2.2.2.1.5 Spain
• 2.3 Asia-Pacific
  • 2.3.1 Market Dynamics
  • 2.3.2 Market Size and Forecast
    • 2.3.2.1 Asia-Pacific Alcohol Use Disorder Market (by Country)
      • 2.3.2.1.1 Japan

3. Global Alcohol Use Disorder Market - Competitive Benchmarking and Company Profiles

• 3.1 Competitive Landscape
  • 3.1.1 Key Strategies and Developments by Company
    • 3.1.1.1 Funding Activities
    • 3.1.1.2 Mergers and Acquisitions
    • 3.1.1.3 Regulatory Approvals
    • 3.1.1.4 Partnerships, Collaborations and Business Expansions
  • 3.1.2 Key Developments Analysis
• 3.2 Company Profiles
  • 3.2.1 Clearmind Medicine Inc.
    • 3.2.1.1 Company Overview
    • 3.2.1.2 Product Portfolio
    • 3.2.1.3 Target Customers/End Users
    • 3.2.1.4 Analyst View
  • 3.2.2 Purdue Pharma L.P.
    • 3.2.2.1 Company Overview
    • 3.2.2.2 Product Portfolio
    • 3.2.2.3 Target Customers/End Users
    • 3.2.2.4 Analyst View
  • 3.2.3 Psyence Biomedical
    • 3.2.3.1 Company Overview
    • 3.2.3.2 Product Portfolio
    • 3.2.3.3 Target Customers/End Users
    • 3.2.3.4 Analyst View
  • 3.2.4 Eli Lilly and Company
    • 3.2.4.1 Company Overview
    • 3.2.4.2 Product Portfolio
    • 3.2.4.3 Target Customers/End Users
    • 3.2.4.4 Analyst View
  • 3.2.5 Tempero Bio, Inc.
    • 3.2.5.1 Company Overview
    • 3.2.5.2 Product Portfolio
    • 3.2.5.3 Target Customers/End Users
    • 3.2.5.4 Analyst View
  • 3.2.6 Nxera Pharma Co., Ltd.
    • 3.2.6.1 Company Overview
    • 3.2.6.2 Product Portfolio
    • 3.2.6.3 Target Customers/End Users
    • 3.2.6.4 Analyst View
  • 3.2.7 Novo Nordisk A/S
    • 3.2.7.1 Company Overview
    • 3.2.7.2 Product Portfolio
    • 3.2.7.3 Target Customers/End Users
    • 3.2.7.4 Analyst View
  • 3.2.8 Adial Pharmaceuticals
    • 3.2.8.1 Company Overview
    • 3.2.8.2 Product Portfolio
    • 3.2.8.3 Target Customers/End Users
    • 3.2.8.4 Analyst View
  • 3.2.9 Alkermes
    • 3.2.9.1 Company Overview
    • 3.2.9.2 Product Portfolio
    • 3.2.9.3 Target Customers/End Users
    • 3.2.9.4 Analyst View
  • 3.2.10 Lundbeck
    • 3.2.10.1 Company Overview
    • 3.2.10.2 Product Portfolio
    • 3.2.10.3 Target Customers/End Users
    • 3.2.10.4 Analyst View

4. Research Methodology